血蛋白质基因分析确定了结直肠癌治疗潜力的预后指标
Xuan Xie1,2, Jiahao Zhou3, Qingbin Wu3
1West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
Carcinogenesis
|January 15, 2026
概括
这项研究确定了用于预测结直肠癌 (CRC) 存活率的新型血蛋白签名. PD-L1被强调为CRC预后的潜在生物标志物和治疗标.
科学领域:
- 在瘤学瘤学.
- 蛋白质组学是指蛋白质组学.
- 生物标志物发现发现
背景情况:
- 血蛋白与结直肠癌 (CRC) 风险有关,但它们的预后价值尚未得到充分研究.
- 了解预后生物标志物对于改善CRC患者的结果至关重要.
研究的目的:
- 确定与CRC患者的整体存活率 (OS) 和无病存活率 (DFS) 相关的血蛋白签名.
- 验证这些特征的预后潜力,并研究PD-L1作为治疗点.
主要方法:
- 在CRC队列 (WCH和UKB) 中测量了367个神经相关血蛋白,使用近距离延伸试验.
- 雇佣LASSO惩罚了Cox回归用于签名开发和门德尔随机化用于遗传关联分析.
- 利用单细胞和空间转录组分析来定位PD-L1表达.
主要成果:
- 开发并验证了用于CRC OS预测的多蛋白签名,在两个队列中具有显著的区分能力.
- 确定了基因决定的PD-L1和OS之间的显著关联.
- PD-L1表达局部化到CRC组织中的上皮和免疫细胞,支持其作用.
结论:
- 建立了用于预测结直肠癌预后的多蛋白签名.
- 鉴定了血PD-L1作为潜在的预后生物标志物和CRC的治疗点.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...


